跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2009-012367-34-BG
EUCTR2009-012367-34-BG进行中（未招募）不适用

A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.

BioCryst Pharmaceuticals, Inc.0 个研究点目标入组 600 人开始时间: 2009年11月10日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
600
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Age =12 years of age, male or female.
  • •2. Able to provide informed consent/assent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.
  • •3. Subject must have at least one of the following clinical presentations at Screening:
  • •a. Oral temperature =38.0 °C (=100.4 °F), =38.6°C (=101.4 °F) tympanic or rectal
  • •b. Oxygen saturation <92%, OR
  • •c. Two out of the following three vital signs:
  • •Respiration rate >24/minute
  • •Heart rate >100/minute
  • •Systolic BP <90 mmHg
  • •4. Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
  • •5. Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).
  • •6. Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as the earlier of either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
  • •7. Either:
  • •Severity of illness that, in the Investigator’s judgment, justifies hospitalization of the subject for supportive care.
  • •Presence of one or more of the following factors:
  • •Age =60 years.
  • •Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.
  • •Current history of congestive heart failure or angina.
  • •Presence of diabetes mellitus, clinically stable or unstable.
  • •Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).
  • •History of chronic renal impairment not requiring peritoneal dialysis.
  • •Serum creatinine > 2.0 mg/dL or >177 µmol/L.
  • •8. Diagnosis of Influenza by satisfying one of the following:
  • •a. Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.
  • •b. Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution’s local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN); 2) prior enrollment of a RAT positive subject into this study at the same institution

排除标准

  • •1. Subjects who have been hospitalized for greater than 24 hours (not including time spent in the Emergency Department).
  • •2. Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.
  • •3. Blood platelet count of < 20 x 1,000,000,000/L at the time of the screening evaluation.
  • •4. Serum bilirubin > 6 mg/dL or >102.6µmol/L at time of screening evaluation.
  • •5. Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.
  • •6. Congestive heart failure of NYHA Class III or Class IV functional status.
  • •7. Serum creatinine > 5.0 mg/dL or >442 µmol/L at time of screening evaluation.
  • •8. Subjects who require peritoneal dialysis.
  • •9. Altered neurologic status as defined by a Glasgow Coma Score of = 9, unless medically induced.
  • •10. Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or breastfeeding.
  • •11. Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. Subjects who have completed treatment 30 days prior to enrollment are not excluded. Hormone treatment for cancer is also not excluded.
  • •12. Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
  • •13. HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral therapy (HAART) for at least 6 months.
  • •14. Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis or Hepatitis B or C not requiring treatment are not excluded.
  • •15. Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
  • •16. Previous treatment with intravenous or intramuscular peramivir.
  • •17. Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
  • •18. Subjects diagnosed with Cystic Fibrosis.
  • •19. Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of screening evaluation.
  • •20.Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.

研究者

相似试验

进行中（未招募）
1 期
A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasisModerate to Severe Chronic Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858
EUCTR2016-003425-42-ITCB Biopharma SR567
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerAdvanced MET-Positive Gastric, Lower Esophageal or Gastroesophageal Junction AdenocarcinomaMedDRA version: 16.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10017766Term: Gastric cancer stage IV NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10017765Term: Gastric cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-004923-11-HUAmgen Inc450
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The Efficacy And Safety Of Certolizumab Pegol In Subjects With Moderate To Severe Chronic Plaque Psoriasis - CIMPACTMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000018190Plaque Psoriasis
EUCTR2014-003492-36-GBCB Biopharma, SPR561
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's Diseasemoderately to severely active Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2018-004614-18-SKEli Lilly and Company1,150
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerAdvanced MET-Positive Gastric, Lower Esophageal or Gastroesophageal Junction AdenocarcinomaMedDRA version: 17.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10017761Term: Gastric cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: LLTClassification code 10017766Term: Gastric cancer stage IV NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10017765Term: Gastric cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-004923-11-BGAmgen Inc600